Eluciderm, Inc., a clinical-stage pharmaceutical company developing small molecule therapeutics designed to promote healing and regenerative repair of injured tissue, announced today that on June 30, ...

BioLab Holdings, Inc. recently announced the launch of a multicenter hybrid platform trial evaluating the clinical real-world ...

Diabetic foot ulcer recurrence may now be more predictable due to a study that identifies compromised skin barrier function ...

Venture Medical, LLC, a leader in advanced wound care solutions, today announced the closing of a strategic investment in ...

In combat zones and emergency rescues, rapid evacuation and treatment can mean the difference between life and death. But ...

Growth factors like epidermal and platelet-derived types showed strong benefits in accelerating healing and reducing ...

ORLANDO, FLORIDA / ACCESS Newswire / July 3, 2025 / RedChip Companies will air interviews with Fathom Holdings, Inc.

With a bunch of diagnostic dead ends piling up, the doctors broadened their view of possibilities, newly considering cancers, ...

PORTLAND, OR, UNITED STATES, July 3, 2025 /EINPresswire.com/ -- The global wound debridement market is set for steady ...

Next‑Gen Amnio-Chorionic Membrane for Enhanced Wound Care is Latest Offering in a Slew of New Products Focused on Increasing ...

High transepidermal water loss with a cutoff of 30.05 g/m2/h was associated with a higher risk for diabetic foot ulcer recurrence.